Indacaterol

Propeller Health Sensor to Be Co-Packaged With Recently Approved Enerzair® Breezhaler® Asthma Medication in Europe

Retrieved on: 
Tuesday, July 7, 2020
Data management, Health, Technology, Hospitals, Software, General Health, Chemical compounds, Drugs, Health, Respiratory therapy, Muscarinic antagonists, RTT, Pregnanes, Progestogens, Mometasone, Indacaterol, Glycopyrronium bromide, Novartis

Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.

Key Points: 
  • Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.
  • View the full release here: https://www.businesswire.com/news/home/20200706005585/en/
    An industry first: Propeller Health digital health solution packaged and prescribed with Enerzair Breezhaler inhaler by Novartis.
  • Enerzair Breezhaler and Propeller sensor and app received approval from the European Commission on in July and will launch across Europe starting in 2020.
  • Healthcare professionals in Europe will have the option to prescribe Enerzair Breezhaler with or without the companion digital health platform.

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Retrieved on: 
Friday, June 5, 2020
Chemical compounds, Drugs, Organic compounds, RTT, Combination drugs, Muscarinic antagonists, Glucocorticoids, Indacaterol, Respiratory therapy, Mometasone, Salmeterol, Fluticasone/salmeterol

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.

Key Points: 
  • Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.
  • These data show the potential of this novel combination product as an effective and convenient therapy in patients with uncontrolled asthma.
  • Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Retrieved on: 
Friday, June 5, 2020
Chemical compounds, Drugs, Organic compounds, RTT, Combination drugs, Muscarinic antagonists, Glucocorticoids, Indacaterol, Respiratory therapy, Mometasone, Salmeterol, Fluticasone/salmeterol

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.

Key Points: 
  • Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.
  • These data show the potential of this novel combination product as an effective and convenient therapy in patients with uncontrolled asthma.
  • Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
  • Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
  • Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).